Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 3
1952 13
1953 62
1954 68
1955 37
1956 40
1957 49
1958 33
1959 25
1960 17
1961 15
1962 26
1963 51
1964 65
1965 40
1966 27
1967 45
1968 30
1969 51
1970 48
1971 54
1972 58
1973 74
1974 107
1975 89
1976 88
1977 109
1978 138
1979 147
1980 213
1981 194
1982 191
1983 224
1984 213
1985 219
1986 184
1987 151
1988 160
1989 135
1990 128
1991 143
1992 138
1993 135
1994 114
1995 119
1996 110
1997 97
1998 82
1999 72
2000 84
2001 77
2002 85
2003 77
2004 86
2005 136
2006 108
2007 113
2008 112
2009 103
2010 84
2011 90
2012 89
2013 78
2014 105
2015 79
2016 90
2017 86
2018 69
2019 75
2020 70
2021 98
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

6,432 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: A randomised controlled trial.
Adebayo JA, Nwafor JI, Lawani LO, Esike CO, Olaleye AA, Adiele NA. Adebayo JA, et al. Niger Postgrad Med J. 2020 Oct-Dec;27(4):317-324. doi: 10.4103/npmj.npmj_275_20. Niger Postgrad Med J. 2020. PMID: 33154284 Free article. Clinical Trial.
AIM: The aim of this study was to compare the efficacy and side effects of oral nifedipine and intravenous hydralazine for control of blood pressure (BP) in severe hypertension in pregnancy. ...Time (min) taken to control the BP was similar between the groups (hydralazi
AIM: The aim of this study was to compare the efficacy and side effects of oral nifedipine and intravenous hydralazine for control of …
Hydralazine for essential hypertension.
Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Kandler MR, et al. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD004934. doi: 10.1002/14651858.CD004934.pub4. Cochrane Database Syst Rev. 2011. PMID: 22071816 Review.
SELECTION CRITERIA: We selected RCTs studying the effect of oral hydralazine compared to oral placebo in patients with primary hypertension. ...MAIN RESULTS: The search strategy did not yield any randomized controlled trials comparing hydralazine to placebo for incl …
SELECTION CRITERIA: We selected RCTs studying the effect of oral hydralazine compared to oral placebo in patients with primary hypert …
HYDRALLAZINE.
[No authors listed] [No authors listed] Lancet. 1977 Feb 12;1(8007):342-3. Lancet. 1977. PMID: 64864 No abstract available.
Hypertension.
LAMB AE, MORRIS GM, WIESEL LL. LAMB AE, et al. Med Times. 1957 Feb;85(2):171-4. Med Times. 1957. PMID: 13399553 No abstract available.
Hydralazine-induced lupus.
Singh S. Singh S. South Med J. 2006 Jan;99(1):6-7. doi: 10.1097/01.smj.0000197302.13225.08. South Med J. 2006. PMID: 16466108 No abstract available.
Parenteral hydralazine revisited.
Powers DR, Papadakos PJ, Wallin JD. Powers DR, et al. J Emerg Med. 1998 Mar-Apr;16(2):191-6. doi: 10.1016/S0736-4679(97)00287-4. J Emerg Med. 1998. PMID: 9543400 Review.
It is reiterated that parenteral hydralazine is the preferred drug for the treatment of severe preeclampsia, but its usefulness in other forms of accelerated hypertension is also addressed. Through comparisons with other established antihypertensive agents, the efficacy an …
It is reiterated that parenteral hydralazine is the preferred drug for the treatment of severe preeclampsia, but its usefulness in ot …
Metabolism of hydralazine.
Israili ZH, Dayton PG. Israili ZH, et al. Drug Metab Rev. 1977;6(2):283-305. doi: 10.3109/03602537708997482. Drug Metab Rev. 1977. PMID: 344023 Review. No abstract available.
Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure.
Finks SW, Finks AL, Self TH. Finks SW, et al. South Med J. 2006 Jan;99(1):18-22. doi: 10.1097/01.smj.0000197121.12352.19. South Med J. 2006. PMID: 16466117 Review.
OBJECTIVE: To review data concerning the incidence and danger of hydralazine-induced systemic lupus erythematosus (SLE) and review how best to monitor patients placed on chronic hydralazine therapy. ...Patients should be closely monitored when initiating hydralaz
OBJECTIVE: To review data concerning the incidence and danger of hydralazine-induced systemic lupus erythematosus (SLE) and review ho …
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A, Coronel J, Cetina L, González-Fierro A, Chavez-Blanco A, Taja-Chayeb L. Dueñas-Gonzalez A, et al. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1433-44. doi: 10.1517/17425255.2014.947263. Epub 2014 Aug 25. Expert Opin Drug Metab Toxicol. 2014. PMID: 25154405 Review.
So far, four epigenetic drugs are approved for myelodysplastic syndrome (MDS) and cutaneous T-cell lymphoma (CTCL). The combination of hydralazine-valproate (TRANSKRIP()) is being repositioned as an oral DNMT and HDAC inhibitor. ...Studies on MDS and CTCL would also eventu …
So far, four epigenetic drugs are approved for myelodysplastic syndrome (MDS) and cutaneous T-cell lymphoma (CTCL). The combination of hy
Clinical pharmacokinetics of hydralazine.
Ludden TM, McNay JL Jr, Shepherd AM, Lin MS. Ludden TM, et al. Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001. Clin Pharmacokinet. 1982. PMID: 7047041 Review. No abstract available.
6,432 results